Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer
- 1 April 1990
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 37 (1) , 44-46
- https://doi.org/10.1016/0090-8258(90)90305-5
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The prognostic and therapeutic value of second‐look laparotomy in advanced ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1988
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- MEASUREMENT OF SERUM TUMOR-MARKER CA-125 IN OVARIAN CARCINOMAS - COMPARATIVE-STUDY BETWEEN ENZYME-IMMUNOASSAY (EIA) AND IMMUNORADIOMETRIC ASSAY (IRA)1988
- A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinomaGynecologic Oncology, 1987
- The clinical significance of pre-operative serum CA 125 in ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY1987
- TUMOR-ASSOCIATED ANTIGEN CA-125 BEFORE AND DURING THE TREATMENT OF OVARIAN-CARCINOMA1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981